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Study Objectives: To evaluate the effect of type 1 narcolepsy (NT1) on anthropometric and endocrine features in childhood/adolescence, focusing on 
patterns and correlates of weight, pubertal development, and growth in treated and untreated patients.
Methods: We collected anthropometric (height, weight, body mass index (BMI) z-scores), pubertal, metabolic, and endocrine data from 72 NT1 patients at 
diagnosis and all available premorbid anthropometric parameters of patients from their pediatric files (n = 30). New measurements at 1-y reassessment in 
patients undergoing different treatments were compared with baseline data.
Results: We detected a high prevalence of overweight (29.2%), obesity (25%), metabolic syndrome (18.8%), and precocious puberty (16.1%), but no signs of 
linear growth alterations at diagnosis. According to anthropometric records, weight gain started soon after NT1 onset. At 1-y follow-up reassessment, sodium 
oxybate treatment was associated with a significant BMI z-score reduction (−1.29 ± 0.30, p < 0.0005) after adjusting for baseline age, sex, sleepiness, and BMI.
Conclusions: NT1 onset in children/adolescents is associated with rapid weight gain up to overweight/obesity and precocious puberty without affecting 
growth. In our study, sodium oxybate treatment resulted in a significant weight reduction in NT1 overweight/obese patients at 1-y follow-up.
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INTRODUCTION
Type 1 narcolepsy (NT1) mainly arises during childhood/ado-
lescence1 with hypersomnolence and cataplexy as heralding 
symptoms.2 Childhood cataplexy differs from the adult form, 
presenting with remarkable facial muscle weakness (“cataplep-
tic facies”) evident even in the absence of emotional triggers.3,4 
Hypnagogic hallucinations and disrupted nocturnal sleep are 
often present from disease onset, whereas sleep paralysis may 
appear later during the disease course.5
Hypocretin deficiency is typical of NT1 and probably 
caused by selective autoimmune destruction of the hypotha-
lamic hypocretin-producing neurons.6,7 Hypocretin deficiency 
affects not only sleep regulation, but also the neuroendocrine 
system with abnormalities in energy balance, feeding behavior, 
glucose metabolism, and modulation of the hypothalamic-pitu-
itary axis.8,9 NT1 patients frequently suffer from obesity,10 type 
2 diabetes,11 and central precocious puberty (PP).12 An associa-
tion with atopic predisposition has also been reported.13 Per-
sonality and behavioral14 and psychiatric symptoms15 hinder 
the correct diagnosis with negative effects on learning, quality 
of life, and psychological development.16
Treatment studies for NT1 are lacking in the pediatric popu-
lation and currently the same pharmacological therapies, such 
as modafinil, sodium oxybate (SO), and venlafaxine17 are used 
both for adults and children (off-label for venlafaxine).
Although obesity has been associated with NT1 in pediatric 
patients,18,19 the time gap between NT1 onset and weight gain, 
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and the possible effects of treatment on weight loss20,21 have 
never been addressed.
Our study compared the anthropometric, metabolic, and en-
docrine data collected in a large pediatric NT1 cohort before 
disease onset, at diagnosis, and at 1-y follow-up.
METHODS
Patients
Seventy-two NT1 patients (35 boys, mean age 11.18 ± 3.13 y) 
underwent endocrinological evaluation. The findings from 
BRIEF SUMMARY
Current Knowledge/Study Rationale: Narcolepsy type 1 has 
been associated with profound metabolic and endocrine alterations 
in young patients, namely overweight/obesity and precocious 
puberty. Our study, based on the collaboration between sleep and 
endocrine pediatric experts, aimed to further investigate whether 
childhood NT1 has been associated with endocrine disorders such 
as overweight/obesity and precocious puberty, and the follow up of 
these comorbidities.
Study Impact: We confirmed the high occurrence of weight increase 
and pubertal alterations in NT1, and, noteworthy, we showed that 
clinically significant weight gain begins soon after disease onset, 
confirming that obesity is an ancillary NT1 symptom. At 1-y follow-up, 
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42 patients enrolled in this study were previously reported.12 
Ethics committee approval and parental written consent were 
obtained.
NT1 Diagnosis
Each patient underwent polysomnography followed by mul-
tiple sleep latency test (MSLT),5 Pediatric Daytime Sleepi-
ness Scale,22 HLA DQB1*06:02 genotyping, brain magnetic 
resonance imaging, and whenever possible, cerebrospinal fluid 
hypocretin-1 (CSF hcrt-1) determination. At discharge, the 
need for behavioral and off-label pharmacological treatment 
with SO monotherapy (as first-line approach chosen to address 
sleepiness, cataplexy and disrupted nocturnal sleep)23,24 or 
modafinil ± venlafaxine (as a second-line approach designated 
to manage daytime symptoms)17 were discussed with the fam-
ily and proposed for each patient. Modafinil was also added if 
hypersomnolence persisted after SO titration.
Anamnesis
Family history (parents and grandparents) of obesity, type 2 
diabetes, dyslipidemia, arterial hypertension, PP, and personal 
history of allergies were investigated by clinical interview.
Endocrine and Pubertal Assessment
Blood levels of thyroid-stimulating hormone (TSH), free thy-
roxine (fT4), free triiodothyronine (fT3), adrenocorticotropic 
hormone (ACTH), serum cortisol, insulin-like growth factor-1 
(IGF-1 and IGF-1 z-score), and prolactin (PRL) were collected 
at 08:00 in patients fasting from midnight onward. Cortisol 
level at 20:00 was determined on blood samples to evaluate 
its circadian rhythm. Twenty-four-hour free urine cortisol was 
also determined. To evaluate growth hormone (GH) pituitary 
secretion 39 children underwent two stimulating tests with 
clonidine (0.1 mg/m2 by mouth) and arginine (0.5 g/kg intra-
venously). Blood samples for GH determination were obtained 
at baseline and after 30, 60, 90, and 120 min. Pubertal devel-
opment was established by Breast-Tanner stage 2 in girls and 
testicular volume ≥ 4 mL in boys (Genital-Tanner stage 2).25,26 
When a discrepancy between chronological age and pubertal 
development was noted, bone age, pelvic ultrasound (in girls), 
and standard gonadotropin-releasing hormone (GnRH) tests 
were performed.
Central PP was confirmed in the presence of all of the fol-
lowing: (1) Tanner stage 2 or higher before the age of 8 y in 
girls or 9 y in boys; (2) plasma luteinizing hormone (LH) levels 
above 5 mIU/mL after GnRH test and (3) normal brain MRI.
Anthropometric and Metabolic Assessment
Height, weight, waist and hip circumferences, body mass index 
(BMI), BMI percentile,27 and recumbent blood pressure and 
heart rate were collected by a physician on the first day of hos-
pitalization. Subsequent auxological follow-up was performed 
at 6 and 12 mo by the same physician (AB) in a dedicated out-
patient clinic. A Harpenden stadiometer was used to measure 
height, and every child was measured three times on the same 
morning to the nearest completed mm. Body weight was mea-
sured in minimal underclothes to the nearest 100 g on accu-
rate and properly calibrated scales. The BMI was calculated 
as weight divided by square of height (kg/m2). Height, weight, 
BMI, and BMI z-score were collected at 1-y follow-up in 56 
children. Sixteen children have not yet reached the 1-y follow-
up because of recent diagnosis.
Fasting blood glucose, basal insulin, total high-density 
(HDL)/low-density lipoprotein (LDL) cholesterol, triglycer-
ides, oral glucose tolerance test,28 and anti-streptolysin O titer 
were collected at 08:00 in patients fasting from midnight on-
ward. Normal weight was defined as BMI < 85th percentile, 
overweight as BMI between 85th and 95th percentile, obesity 
as BMI > 95th percentile.29 Metabolic syndrome was defined 
using Cook criteria for children/adolescents30 fulfilled by waist 
circumference ≥ 90th percentile (sex/age) and at least one of 
the following criteria: fasting glucose ≥ 110 mg/dL, triglycer-
ides ≥ 110 mg/dL, HDL ≤ 40 mg/dL, and blood pressure ≥ 90th 
percentile (age/sex/height). The responses to the oral glucose 
tolerance test were analyzed by calculating the area under the 
curve (trapezoidal method).
BMI z-score (weight adjusted for height, sex, and age)31 was 
calculated at baseline in all subjects. At least two BMI z-scores 
between the age of 3 y and NT1 onset were available for 30 
patients from general pediatric records. After the parental de-
cision on treatment, patients were regularly followed up with 
weekly telephone interviews for 1 mo (SO titration period) and 
clinical evaluations after 3, 6, and 12 mo.
Statistical Analysis
Continuous and categorical data were explored with descrip-
tive statistics (mean ± standard deviation [SD]) and frequency 
in the whole population and in patient subgroups. Nonpara-
metric statistical approaches were used for between-group 
comparisons (Mann-Whitney U or chi-square tests) and for 
within-subject comparisons (Wilcoxon signed-rank or chi-
square tests) for continuous or categorical data, respectively. 
Multivariate linear regression analyses tested treatments im-
pact on BMI z-score change adjusting for baseline features. 
A value of p < 0.05 was considered statistically significant.
RESULTS
Mean age at onset of first symptom (either somnolence or cata-
plexy) was 8.68 ± 2.50 y, mean delay between NT1 onset and 
diagnosis was 1.70 ± 2.13 y, and 56.5% of the sample had pre-
viously received wrong diagnoses. Wrong diagnosis included 
obesity, unspecified metabolic disorder, unspecified hormonal/
endocrinological disorder, mononucleosis, psychological dis-
orders, depression, psychomotor retardation, attention deficit 
hyperactivity disorder, encephalitis, epilepsy, chorea, complex 
tic disorder, myasthenia gravis, myopathy, parasomnia, un-
specified hypersomnia, and Kleine-Levin syndrome.
CSF hcrt-1 concentration (61 cases) was 24.01 ± 28.99 
pg/mL. HLA DQB1*06:02 allele was present in 68 children 
(94.4%). Four children with HLA DQB1*06:02 negative geno-
type had CSF hcrt-1 concentration below 110 pg/mL.32 MSLT 
confirmed NT1 (mean sleep latency 4.21 ± 3.24 min, with 
4.07 ± 1.07 sleep-onset rapid eye movements periods) in 64 
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CSF hcrt-1 deficiency (Table 1). There were 20.8% of patients 
with inhaler allergies and 11.1% with food allergies, 7.6% with 
atopic dermatitis, and 66.7% had high anti-streptolysin O titers 
(> 200 UI/mL).
Endocrine and Pubertal Assessment
No thyroid or adrenal gland alterations were detected. Indeed, 
mean ± SD blood values of TSH, ACTH, serum 08:00 and 
20:00 cortisol were 2.08 ± 1.11 μUI/mL, 24.89 ± 13.77 pg/mL, 
116.0 ± 60.95 ng/mL, and 28.87 ± 16.40 ng/mL, respectively. 
Prolactin blood levels were normal (mean value 15.13 ± 7.19 
ng/mL). IGF-1 z-score was within normal range in all patients 
(mean value 0.26 ± 1.01, range −1.27 to 2.27). Among the 39 
patients tested with the arginine and clonidine tests, 23 (5 with 
normal weight, 18 overweight/obese) had blunted GH concen-
tration (below 8 ng/mL) in at least one determination. We used 
the 8 ng/mL cutoff as indicated by Italian guidelines.33
Twenty-five children were prepubertal, 35 were pubertal 
(menarche mean age 11.17 ± 1.13 y), and 12 (16.07%, 6 girls) 
had PP, fulfilling the criteria mentioned in the Methods section. 
None of these children had parents with PP. Eleven PP chil-
dren underwent GnRH analogous treatment. Comparing chil-
dren with (n = 12) and without (n = 60) PP, no differences in 
sleep-related parameters, overweight/obesity, allergies, family 
history, or metabolic characteristics were detected. However, 
children with PP more frequently received wrong diagnoses 
(Table 2: 91.7% vs. 49.1%, p = 0.007).
Anthropometric and Metabolic Characteristics
All children were of regular height (mean height z-score 
0.72 ± 1.07) with a projected height within the range of their 
target height. There were 29% and 25% of patients who were 
overweight and obese, respectively, and 18.8% had metabolic 
syndrome. The overweight/obese children showed worse 
MSLT performances than those with normal weight (Table 3). 
Overweight/obese cases had higher diastolic (69.21 ± 10.60 vs. 
63.29 ± 9.31 mmHg, p = 0.046) and systolic (114.14 ± 10.76 vs. 
103.04 ± 12.89 mmHg, p = 0.001) blood pressure, lower HDL 
cholesterol (50.50 ± 13.48 vs. 59.70 ± 14.29 mg/dL, p = 0.012), 
higher insulin area under the curve values (11903.6 ± 9313.82 
vs. 7154.89 ± 3469.77 μU/mL, p = 0.015), and higher preva-
lence of metabolic syndrome (28.6% vs. 6.9%, p = 0.027) 
when compared to a normal-weight cohort. No significant dif-
ferences emerged in family history, allergies or PP prevalence 
(Table 4).
Anthropometric Characteristics before NT1 Onset
We analyzed anthropometric characteristics in a 2-y period 
before NT1 onset in the subset of 30 patients for whom writ-
ten medical records were available. The within-subject com-
parison of three values of mean BMI z-score included the first 
one 2 y before NT1 onset (Time-2), referred to a mean age 
of 5.61 ± 2.49 y, the second one 1 y before NT1 (Time-1) re-
ferred to a mean age of 6.64 ± 2.59 y, and the third one at the 
time of diagnosis (T0). Weight gain started close to NT1 onset 
with significant changes from T-1 to T0. Overweight/obesity 
increased from 16.7% at T-2 and 16.6% at T-1 to 50.0% at T0 
(Figure 1).
1-Year Follow-Up
Fifty-six children were reevaluated after 1 y. Children who 
for different reasons were not included in the follow-up had 
no significant differences from the others at NT1 diagnosis 
time. Thirty-five were treated with SO alone (n = 16) or in 
association with modafinil (n = 19), 14 with modafinil, and 
7 were untreated. No statistical differences of BMI or BMI 
z-scores (Kruskal-Wallis test, p = 0.197 and p = 0.301 re-
spectively) were found between the four groups (untreated, 
treated with SO, treated with modafinil, treated with SO 
and modafinil) at baseline. All had a regular height after 1 
y. Mean ± SD of growth velocity calculated from diagnosis 
time to follow-up was 1.84 ± 5.93. Thirteen patients had a 
growth velocity lower than 2 SD, but all of these had al-
ready started pubertal development at diagnosis. Patients 
treated with SO had a lower BMI z-score at follow-up com-
pared to baseline (0.50 ± 1.23 vs. 1.19 ± 1.00, p < 0.0005) and 
obesity decreased from 31.42% to 17.14%, and overweight 
from 25.71% to 17.14% in this group. Patients without SO 
showed comparable BMI z-scores at baseline and at follow-
up (Table 5).
Table 1—Demographic, endocrine, and immunological 
characteristics from 72 children with type 1 narcolepsy.
Sex, male % 48.6
Age at observation, y 11.18 ± 3.13
Age at onset of first symptom (EDS or cataplexy), y 8.68 ± 2.50
Age at diagnosis, y 10.38 ± 2.24
Disease duration, y 2.19 ± 2.26
Diagnostic delay, y 1.70 ± 2.13
Patients with wrong diagnosis, % 56.5
Medical examination (without diagnosis), n 1.13 ± 1.36
Hospital admission (without diagnosis), n 0.84 ± 1.18
CSF hypocretin 1, pg/ml (61) 24.01 ± 28.99
HLA DQB1*06:02, % 94.4
Obesity familial predisposition, % 24.6 
Dyslipidemia familial predisposition, % 29.2
Type 2 diabetes familial predisposition, % 30.8
Hypertension familial predisposition, % 60.0
Overweight/obese, % 29.2/25.0
Body mass index, kg/m² 23.11 ± 5.31
Metabolic syndrome, % 18.80
Precocious puberty (PP), % 16.07
NT1 onset before cut-off for PP, % 56.9
Diagnosis before cut-off for PP, % 27.8
Inhaler allergy, % 20.8
Food allergy, % 11.1
Atopic dermatitis, % 7.6
ASO ≥ 200 IU/ml, % 66.7
Positive throat culture for GAS, % 24.2
Values are indicated as mean ± standard deviation or percent. ASO, 
anti-streptolysin O; CSF, cerebrospinal fluid; EDS, excessive daytime 
sleepiness; GAS, group A streptococcus; HLA, human leukocyte antigen; 
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In order to establish the effect of treatment on weight, we 
calculated the BMI z-score difference (outcome) and applied a 
linear logistic regression considering treatment type as predic-
tors (SO, modafinil, and combined therapy versus no treatment 
as reference group). Correcting for baseline features (Model 1; 
age, sex, BMI z-score, disease duration), and also for sleepi-
ness level (Model 2; Pediatric Daytime Sleepiness Scale), only 
SO monotherapy maintained a significant effect (Table 6, 
Figure 2).
DISCUSSION
Investigating weight and growth changes in NT1 children 
before disease onset, at diagnosis, and at 1-y follow-up, we 
confirmed the high occurrence of overweight/obesity among 
this population. Our study also demonstrated the temporal cor-
relation between weight gain and NT1 onset, and the positive 
effect of SO treatment on weight.
The prevalence rates of both inhaler and food allergies were 
similar to those of other studies34 with a negligible difference 
from the general population.35,36
The high prevalence of wrong diagnosis in patients with 
comorbid central PP and the diagnostic delay highlight the 
challenge of diagnosing NT1 also in pediatric populations and 
suggest obesity should be considered an ancillary though po-
tentially misleading NT1 symptom.
Twenty-three children had GH levels after stimulation37 be-
low the current cutoff for GH deficiency,33 suggesting an effect 
on pituitary GH secretion, despite normal IGF1 levels. This 
Table 2—Comparison between NT1 children with and without precocious puberty.
 NT1 with PP (n = 12) NT1 without PP (n = 60) p value
Sex, male % 50 48.3 NS
Age at observation, y 8.68 ± 0.84 11.68 ± 3.18 0.001
Age at onset of first symptom (EDS or cataplexy), y 6.64 ± 1.12 9.09 ± 2.51 0.001
Age at diagnosis, y 8.27 ± 0.84 10.80 ± 2.91 0.001
Disease duration, y 2.18 ± 1.59 2.19 ± 2.38 NS
Diagnostic delay, y 1.62 ± 1.32 1.71 ± 2.27 NS
Patients with wrong diagnosis, % 91.7 49.1 0.007
Medical examination (without diagnosis), n 1.58 ± 1.31 1.04 ± 1.36 NS
Hospital admission (without diagnosis), n 1.17 ± 1.34 0.77 ± 1.15 NS
CSF hypocretin 1, pg/ml (61) 100 93.3 NS
HLA DQB1*06:02, % 16.24 ± 19.99 25.92 ± 30.66 NS
Obesity familial predisposition, % 16.7 26.4  NS
Dyslipidemia familial predisposition, % 16.7 32.1 NS
Type 2 diabetes familial predisposition, % 41.7 28.3 NS 
Hypertension familial predisposition, % 41.7 64.2 NS
Onset before PP cut-off, % 100 48.3 0.001
Diagnosis before PP cut-off, % 58.3 21.7 0.01
Overweight/obese, % 41.7/25 26.7/25 NS
Body mass index 21.06 ± 2.87 23.52 ± 5.61 NS
Metabolic syndrome, % 33.3 16.4 NS
Systolic blood pressure, mmHg 106.86 ± 11.52 108.84 ± 13.32 NS
Diastolic blood pressure, mmHg 63.43 ± 8.26 66.65 ± 10.60 NS
HDL cholesterol, mg/dL 51.50 ± 13.06 55.43 ± 14.79 NS
LDL cholesterol, mg/dL 103.00 ± 20.07 100.10 ± 28.94 NS
Glucose AUC, mg/dL 13678.50 ± 2041.60 14060.74 ± 2093.13 NS
Insulin AUC, μU/mL 7069.50 ± 3140.02 10205.97 ± 8050.16 NS
Fasting plasma glucose, mg/dL 78.17 ± 6.22 78.28 ± 7.30 NS
Fasting plasma insulin, μU/mL 11.47 ± 5.61 13.38 ± 10.81 NS
Inhaler allergy, % 25 20 NS
Food allergy, % 16.7 10 NS
Atopic dermatitis, % 0 9.3 NS
ASO ≥ 200 IU/mL, % 75 64.7 NS
Positive throat culture for GAS, % 33.3 22.2 NS
Values are indicated as mean ± standard deviation or percent. ASO, anti-streptolysin O; AUC, area under the curve; CSF, cerebrospinal fluid; GAS, group 
A streptococcus; HLA, human leukocyte antigen; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NT1, type 1 narcolepsy; n, number; PP, 
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finding allows us to speculate that BMI alterations per se can 
modify the GH response to stimulation tests,38 and the NT1-
nocturnal sleep disruption might be responsible for the altered 
GH secretion to stimulation tests. Further studies on sponta-
neous circadian GH secretion in NT1 children will hopefully 
add knowledge to the role and cause of GH-modified secretion 
during puberty.
A subgroup of patients (25.4%) had a growth velocity lower 
than the expected value, but they were all pubertal at diag-
nosis and growth velocity is known to slow down in the final 
phase of pubertal development.39 Further studies could clarify 
whether NT1 patients had a final height penalized by a PP or 
anticipated puberty or dysregulated GH secretion.
The high prevalence of PP12 (16.07% vs. 0.015%) was sex 
equivalent,40 as opposed to the nearly 10:1 female to male ratio 
in idiopathic central PP, suggesting a causal role of NT1. Inter-
estingly, the menarche occurred at a mean age of 11.17 ± 1.13 
y in NT1 pubertal girls, approximately 1 y before the mean 
menarche age in Italian adolescents.41 This signal of PP or early 
puberty points to a complex and unknown interplay of hypocret-
inergic system and hypothalamus-pituitary regulation, particu-
larly GnRH secretion, requiring further studies on the issue.42
Changes in eating behavior and basal metabolism,43 and au-
tonomic dysregulation,44 altering the circadian rhythm of GH45 
and TSH46 secretion, have been invoked to explain the associa-
tion between NT1 and obesity.17,18 Even if our study could not 
explain why NT1 causes overweight (29.2%) and obesity (25%) 
in a clinical population free from major medical comorbidi-
ties, we did confirm higher prevalence rates than in the general 
Italian population (overweight 20.9%, obesity 9.8%).47 General 
pediatric records showed a stable overweight-obesity preva-
lence (roughly 17%) before NT1 onset peaking up to 50% at 
diagnosis, proving that obesity appears closely after NT1 onset. 
Overweight and obese children17 showed a greater prevalence 
of metabolic alterations, with a higher risk of hypertension, 
insulin resistance, lower HDL cholesterol, and overall higher 
prevalence of metabolic syndrome compared to normal weight 
NT1 children. PP and overweight/obesity are not mutually as-
sociated in NT1, but NT1 onset at a younger age is an intrinsic 
risk factor for PP.
Our study provided new data on NT1 clinical history and the 
effect of SO on weight and BMI. As already reported in adults 
with NT1, SO induced weight loss in obese/overweight children 
without causing normal-weight children to be underweight. We 
Table 3—Comparison of sleep-related parameters between normal weight and overweight/obese NT1 children.
NT1 with Overweight-Obesity 
(n = 39)
NT1 without Overweight-
Obesity (n = 33) p value
Epworth Sleepiness Scale 14.38 ± 3.79 13.00 ± 4.36 NS
PDSS 19.69 ± 5.23 16.88 ± 6.62 NS
Nap numbers 4.67 ± 3.12 5.21 ± 3.17 NS
Nap TST 118.67 ± 68.92 123.64 ± 79.06 NS
Nap with SOREMP 2.00 ± 1.24 1.88 ± 1.11 NS
Nocturnal time in bed 533.73 ± 64.66 541.97 ± 79.07 NS
Nocturnal total sleep time, min 487.15 ± 77.82 487.15 ± 77.82 NS
Nocturnal sleep latency, min 5.70 ± 6.34 5.27 ± 4.18 NS
Nocturnal REM sleep latency, min 40.43 ± 62.22 31.39 ± 49.32 NS
Nocturnal SOREMP, % 65.8 65.6 NS
Wakefulness after sleep onset 56.56 ± 54.46 53.82 ± 37.00 NS
Nocturnal sleep efficiency, % 88.45 ± 9.92 89.22 ± 6.54 NS
Oxygen desaturation index 0.89 ± 1.43 0.58 ± 1.56 NS
Periodic leg movements index 21.41 ± 16.31 22.76 ± 18.66 NS
MSLT sleep latency, min 4.02 ± 3.30 4.42 ± 3.20 NS
MSLT SOREMP number 4.21 ± 1.02 3.91 ± 1.12 NS
SL1 3.18 ± 4.70 4.88 ± 5.07 0.02304
SL2 2.95 ± 2.96 4.82 ± 5.11 NS
SL3 3.73 ± 4.37 3.68 ± 2.89 NS
SL4 3.70 ± 4.15 3.1 ± 3.00 NS
SL5 4.89 ± 5.69 3.72 ± 2.46 NS
REM1 1.60 ± 1.61 1.86 ± 0.95 NS
REM2 2.21 ± 1.95 3.20 ± 1.67 0.020848
REM3 2.11 ± 1.45 3.54 ± 2.15 0.025532
REM4 1.97 ± 1.01 3.6 ± 1.94 0.006655
REM5 2.34 ± 1.21 2.39 ± 1.40 NS
Values are indicated as mean ± standard deviation or percent. MSLT, multiple sleep latency test; NS, not significant; PDSS, pediatric daytime sleepiness 
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Table 4—Comparison between NT1 children with and without overweight/obesity.
 NT1 with Overweight-Obesity 
(n = 39)
NT1 without Overweight-
Obesity (n = 33) p value
Sex, male % 53.8 42.4 NS
Age at observation, y 11.08 ± 2.98 11.29 ± 3.34 NS
Age at onset of first symptom, y 8.69 ± 2.51 8.66 ± 2.54 NS
Age at diagnosis, y 10.33 ± 2.53 10.44 ± 3.21 NS
Disease duration, y 2.20 ± 2.01 2.18 ± 2.56 NS
Diagnosis delay, y 1.61 ± 1.87 1.80 ± 2.44 NS
Wrong diagnosis, % 57.9 54.8 NS
Medical examination without diagnosis, n 1.27 ± 1.45 0.97 ± 1.25 NS
Hospital admission without diagnosis, n 0.76 ± 1.24 0.94 ± 1.12 NS
HLA DQB1*06:02, % 92.3 97 NS
CSF hypocretin 1, pg/mL 25.11 ± 26.48 22.63 ± 32.34 NS
Obesity familial predisposition, % 21.2 28.1 NS
Dyslipidemia familial predisposition, % 27.3 31.3 NS
Type 2 diabetes familial predisposition, % 27.3 34.4 NS
Hypertension familial predisposition, % 51.5 68.8 NS
Body mass index, kg/m² 26.11 ± 5.15 19.58 ± 2.69 < 0.001
Age at weight gain, y 8.57 ± 2.55 9.12 ± 2.43 NS
Metabolic syndrome, % 28.6 6.9 0.027
Precocious puberty, % 20.5 12.1 NS
Onset before PP cutoff, % 56.4 57.6 NS
Diagnosis before PP cutoff, % 23.1 33.3 NS
Systolic blood pressure, mmHg 114.14 ± 10.76 103.04 ± 12.89 0.001
Diastolic blood pressure, mmHg 69.21 ± 10.60 63.29 ± 9.31 0.046
HDL cholesterol, mg/dL 50.50 ± 13.48 59.70 ± 14.29 0.012
LDL cholesterol, mg/dL 103.75 ± 33.99 97.30 ± 22.47 NS
Glucose AUC, mg/dL 14228.71 ± 2334.52 13713.46 ± 1708.79 NS
Insulin AUC, μU/mL 11903.6 ± 9313.82 7154.89 ± 3469.77 0.015
Fasting plasma glucose, mg/dL 78.81 ± 8.02 77.64 ± 5.92 NS
Fasting plasma insulin, μU/mL 15.89 ± 13.27 10.39 ± 4.18 NS
Inhaler allergy, % 15.4 27.3 NS
Food allergy, % 10.3 12.1 NS
Atopic dermatitis, % 8.3 6.7 NS
ASO ≥ 200 IU/mL, % 60.5 76 NS
Positive throat culture for GAS, % 25.9 22.2 NS
Values are indicated as mean ± standard deviation or percent. ASO, anti-streptolysin O; AUC, area under the curve; CSF, cerebrospinal fluid; GAS, group 
A streptococcus; HLA, human leukocyte antigen; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NT1, type 1 narcolepsy; n, number; PP, 
precocious puberty; y, year.
Table 5—Comparison between children with (Group 1) and without (Group 2) sodium oxybate therapy.
Group 1 (n = 35) Group 2 (n = 21)
T0 T1 Wilcoxon Test T0 T1 Wilcoxon test
mean ± SD mean ± SD p value mean ± SD mean ± SD p value
Age at observation, y 11.27 ± 2.96 12.18 ± 2.98 < 0.001 10.1 ± 2.39 11.01 ± 2.38 0.000161
Height, cm 148.83 ± 16.6 152.5 ± 15.38 0.000013 142.81 ± 14.5 149.51 ± 13.26 0.000087
Weight, kg 55.06 ± 22.23 52.67 ± 19.52 0.168587 46.55 ± 16.34 51.5 ± 15.03 0.000718
BMI 23.99 ± 5.84 21.99 ± 5.53 0.000415 22.24 ± 4.45 22.59 ± 3.47 0.305198
Height z-score 0.68 ± 0.93 0.39 ± 1.04 0.053268 0.59 ± 0.96 0.79 ± 1.16 0.476136
Weight z-score 1.29 ± 1.05 0.63 ± 1.16 0.000007 1.03 ± 0.77 1.08 ± 0.84 0.590064
BMI z-score 1.19 ± 1 0.5 ± 1.23 0.000007 1.02 ± 0.9 1.03 ± 0.76 0.986134
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may only speculate that lipolysis stimulation,48 GH-circadian 
rhythm reconstruction,49 potential changes in sympathetic ac-
tivity,50 changes in eating behavior, or the recovery of diurnal 
daytime motor activity and nocturnal slow-wave sleep may all 
be associated with the positive effect of SO on weight loss in 
these patients.
Although our study suffers from limitations regarding the 
not-randomized intervention, and the small number of pa-
tients with available medical records (30 of 72), we highlight 
the absence of significant differences between the treatment 
subgroups of NT1 patients. Despite performing comparisons 
between relatively small groups of patients for both premorbid 
and follow-up weight changes, the data were numerically suf-
ficient to reach statistical significance and answer our research 
questions on the time course of weight changes, NT1 onset, 
and follow-up with and without treatment. Another impor-
tant study limitation is the absence of a control group. Further 
randomized studies are necessary to address the links between 
NT1, obesity, and PP, and to understand how SO treatment af-
fects weight balance.
CONCLUSIONS
We confirm that NT1 is associated with obesity and PP when 
appearing at a young age. It is not totally clear if linear growth 
could be affected in the long term. SO treatment promotes 
weight loss, especially in overweight/obese patients.
ABBRE VI ATIONS
ACTH, adrenocorticotropic hormone
ASO, anti-streptolysin O titers
Figure 1—Body mass index (BMI) z-scores until NT1 onset. 
The graph shows the individual time course of BMI z scores obtained 
through general pediatric records available in 30 patients at a mean age 
of 5.61 ± 2.49 y (T-2), and 6.64 ± 2.59 y (T-1), and at diagnosis (T0) with 
evidence of a significant increase occurring between T-1 and T0 around 
NT1 onset.
Figure 2—Body mass index (BMI) z-scores before NT1 
onset and after one year of therapy.
The graph shows the individual evolution of BMI z-scores before 
diagnosis (T-2, T-1), at diagnosis (T0), and at 1-year follow-up (FU). 
Different treatments (labeled by color codes) were used after diagnosis 
with sodium oxybate inducing a significant reduction of BMI z-score.
Table 6—Effect of treatments on body mass index z-score change.
 
 
Model 1 Model 2
SO Modafinil SO+Modafinil SO Modafinil SO+Modafinil
Coefficient −1.32 −0.33 −0.56 −1.28 −0.29 −0.54
Standard error 0.3 0.29 0.28 0.3 0.29 0.28
p value 0 0.267 0.05 < 0.001 0.322 0.061
95% CI: lower −1.91 −0.91 −1.12 −1.89 −0.89 −1.1
95% CI: upper −0.72 0.25 < 0.001 −0.69 0.29 0.02
Corrected for baseline body mass index z-score, age, sex, disease duration (Model 1) and corrected for body mass index z-score, age, sex, disease 






































































































1656Journal of Clinical Sleep Medicine, Vol. 12, No. 12, 2016
V Ponziani, M Gennari, F Pizza, et al. Weight and Growth in Narcoleptic Children
BMI, body mass index






HLA, human leucocyte antigen
IGF-1, insulin-like growth factor-1
LDL, low-density lipoprotein
LH, luteinizing hormone
MRI, magnetic resonance imaging
MSLT, multiple sleep latency test
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